Alphatec (NASDAQ:ATEC) General Counsel Tyson Eliot Marshall Sells 70,000 Shares

Alphatec Holdings, Inc. (NASDAQ:ATEC) General Counsel Tyson Eliot Marshall sold 70,000 shares of the business’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $19.51, for a total value of $1,365,700.00. Following the completion of the transaction, the general counsel owned 368,331 shares in the company, valued at $7,186,137.81. This trade represents a 15.97% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Alphatec Stock Up 3.6%

Shares of NASDAQ:ATEC traded up $0.70 on Friday, reaching $20.31. The company had a trading volume of 2,306,833 shares, compared to its average volume of 2,126,413. The stock has a 50-day moving average price of $16.48 and a 200 day moving average price of $14.17. Alphatec Holdings, Inc. has a twelve month low of $8.69 and a twelve month high of $21.16. The company has a quick ratio of 1.77, a current ratio of 2.88 and a debt-to-equity ratio of 23.22. The stock has a market capitalization of $3.02 billion, a P/E ratio of -17.97 and a beta of 1.17.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings data on Thursday, October 30th. The medical technology company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.09. The business had revenue of $196.50 million during the quarter, compared to the consensus estimate of $182.78 million. The company’s revenue for the quarter was up 30.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.28) earnings per share. Alphatec has set its FY 2025 guidance at EPS. On average, equities analysts expect that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Stifel Nicolaus initiated coverage on Alphatec in a research report on Tuesday, October 28th. They issued a “buy” rating and a $20.00 target price for the company. JPMorgan Chase & Co. assumed coverage on shares of Alphatec in a research note on Friday, October 24th. They issued an “overweight” rating and a $19.00 price objective for the company. Wells Fargo & Company lifted their target price on shares of Alphatec from $14.00 to $16.00 and gave the company an “overweight” rating in a research report on Thursday, October 16th. Lake Street Capital set a $25.00 target price on shares of Alphatec and gave the company a “buy” rating in a research note on Friday, October 31st. Finally, Canaccord Genuity Group increased their price target on shares of Alphatec from $20.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $22.00.

Institutional Trading of Alphatec

Several hedge funds have recently modified their holdings of the company. Aster Capital Management DIFC Ltd acquired a new position in shares of Alphatec in the 3rd quarter worth approximately $34,000. Osterweis Capital Management Inc. acquired a new stake in Alphatec during the 2nd quarter valued at $37,000. China Universal Asset Management Co. Ltd. bought a new position in Alphatec in the 3rd quarter valued at $73,000. Nisa Investment Advisors LLC boosted its stake in Alphatec by 22.4% in the second quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock worth $63,000 after purchasing an additional 1,045 shares in the last quarter. Finally, State of Alaska Department of Revenue acquired a new position in Alphatec in the third quarter worth $120,000. Institutional investors and hedge funds own 66.35% of the company’s stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.